FDA Lifts Tirzepatide Shortage Status: What It Means for Patients Relying on Compounded Versions and why they reversed their decision

FDA Removes Tirzepatide (Mounjaro, Zepbound) from Drug Shortage List: What It Means for Patients Using Compounded Versions and Reasons Behind There Sudden Reversal

Tirzepatide No Longer in Short Supply: Impact on Compounded Medications for Weight Loss

Tirzepatide No Longer in Short Supply: Impact on Compounded Medications for Weight Loss

As of October 2024, the FDA has officially removed tirzepatide  (the active ingredient in Mounjaro and Zepbound) from its drug shortage list. This change follows months of high demand for tirzepatide, which is used for both diabetes and weight-loss treatments. Due to the rising popularity of GLP-1 medications for weight loss, many patients experienced difficulties obtaining them. Eli Lilly, the manufacturer, increased production capacity, restoring full availability in pharmacies. Lilly's drugs  have recently taken the world of weight loss by storm, however, this has impacted providers and patients who relied on affordable, effective compounded versions of the drug. The good news is that due to pressure from advocacy groups, they reversed their decision...for now.

Impact on Compounded Tirzepatide

During the shortage, compounded tirzepatide provided a legal and accessible alternative, allowing pharmacies to create versions by combining drug ingredients or altering the dose, sometimes with added vitamins like B-12. Now that the shortage has been resolved, compounding pharmacies are no longer permitted to produce and sell new tirzepatide compounds, which will affect many patients currently using compounded versions for weight loss.

This change will likely raise the cost of tirzepatide for patients who found the compounded version to be a more affordable option. The FDA’s  decision may impact tirzepatide costs in two main ways:

Higher Costs for Brand-Name Versions

Mounjaro and Zepbound, the FDA-approved brands, are considerably more expensive than compounded medications. Brand-name drugs often have higher prices due to research, development, and marketing costs, as well as corporate pricing strategies. Without compounded versions, pharmaceutical companies can set higher prices due to lack of competition. The potential for significant profits makes it worthwhile for companies to defend these price points in court.

For example, Mounjaro for diabetes can cost patients without insurance $1,000 to $1,200 per month, with Zepbound similarly priced for weight loss. Insurance may cover part of the cost, but most insurance plans exclude weight-loss medications, despite evidence supporting their health benefits, like reducing obesity-related comorbidities.

Lower Costs for Compounded Versions

Compounded tirzepatide, produced during the shortage, was often significantly cheaper because compounding pharmacies are not bound by major pharmaceutical pricing. Patients could save hundreds of dollars monthly through compounded alternatives, particularly when obtained through specialty clinics or anti-aging and weight-loss providers.

Now, with compounded tirzepatide unavailable, patients must switch to the pricier brand-name options, which could strain budgets for those previously using compounded forms for affordability.

Future Pricing Trends

With Eli Lilly increasing production, there’s hope that the higher availability may eventually influence prices through competition or expanded insurance coverage. However, in the near term, the cost gap between compounded and brand-name versions will remain substantial. As a profit-driven company, Eli Lilly will likely aim to maintain high pricing to maximize returns.

Patients transitioning to branded medications should consult their healthcare providers and check with insurance companies for rebates, discounts, or generic alternatives if available. Semaglutide is a generic medication, a similar medication to tirzepatide, and might remain a more affordable choice for some patients.

Temporary Access for Compounded Tirzepatide

Fortunately, the FDA has granted a 60-day grace period during which compounded pharmacies can fulfill pre-existing tirzepatide orders. After this period, compounded tirzepatide will no longer be legally available unless a new shortage occurs. In response to public demand, the FDA has agreed to review its decision, which was prompted by a lawsuit from the Outsourcing Facilities Association. The U.S. FDA agreed on October 11, 2024, to reconsider its decision barring compounding pharmacies from producing their own versions of Eli Lilly's popular weight loss and diabetes drugs, Mounjaro and Zepbound due to the outsourcing facilities association. This association represents the compounding industry and argues that compounded options provide a cheaper, essential alternative for weight loss, especially given limited insurance coverage.

The lawsuit, now on hold by U.S. District Judge Mark Pittman, highlights ongoing shortages and the demand for compounded alternatives, which offer solutions for patients unable to access or afford brand-name options. For now, some pharmacies can still fill compounded tirzepatide prescriptions, and we’ll monitor the FDA’s and courts' actions to see what the future holds for patients, providers, and pharmacies.

What This Means for Patients

For those relying on compounded tirzepatide, this change means switching to the FDA-approved options—Mounjaro (for diabetes) and Zepbound (for weight management). Patients using compounded versions should consult with their healthcare providers to facilitate a smooth transition and explore potential insurance coverage for the brand-name medications.

Although compounded medications may offer more affordable alternatives, FDA-approved options are rigorously regulated for safety and efficacy. Now that Eli Lilly can meet demand, brand-name availability should improve, reducing the need for compounded alternatives.

 

Future Outlook for GLP-1 Agonists and FDA Regulations

The resolution signals improved supply and manufacturing, making tirzepatide widely available for diabetes and weight management. Eli Lilly’s continued investment in new production facilities aims to prevent future shortages, a positive development for patients relying on these medications. The more hopeful news is the FDA’s willingness to reconsider its decision, potentially allowing for compounded options to help combat obesity, one of the nation’s leading health risks.

If you’re interested in a consultation to discuss weight loss programs with Dr. Mackey and learning more about GLP-1 medications or discussing other options, Contact us at 561-277-8260 to set up an initial consultation.

 

Foley & Lardner LLP   BioSpace